XBIO financial statements and SEC filings
XBIO annual income statement
| Fiscal period end | Revenue | Operating income | Net income | SEC filing |
|---|
| 2025-12-31 | $2.98M | -$2.83M | -$2.68M | 10-K |
| 2024-12-31 | $2.50M | -$4.20M | -$3.96M | 10-K |
| 2023-12-31 | $2.54M | -$4.52M | -$4.13M | 10-K |
| 2022-12-31 | $1.71M | -$6.72M | -$6.55M | 10-K |
| 2021-12-31 | $1.16M | -$5.75M | -$5.65M | 10-K |
| 2020-12-31 | $436.94K | -$13.94M | -$10.89M | 10-K |
XBIO annual balance sheet
| Fiscal period end | Assets | Liabilities | Equity | SEC filing |
|---|
| 2025-12-31 | $8.36M | $968.02K | $7.40M | 10-Q |
| 2024-12-31 | $6.90M | $894.26K | $6.01M | 10-K |
| 2023-12-31 | $10.61M | $809.59K | $9.80M | 10-K |
| 2022-12-31 | $14.72M | $1.07M | $13.65M | 10-K |
| 2021-12-31 | $19.82M | $1.42M | $18.39M | 10-K |
| 2020-12-31 | $13.18M | $963.97K | $12.22M | 10-K |
XBIO annual cash flow
| Fiscal period end | Operating cash flow | Capital expenditure | Financing cash flow | SEC filing |
|---|
| 2025-12-31 | -$2.29M | – | $4.00M | 10-K |
| 2024-12-31 | -$2.82M | – | $0.00 | 10-K |
| 2023-12-31 | -$4.11M | – | – | 10-K |
| 2022-12-31 | -$4.65M | – | $0.00 | 10-K |
| 2021-12-31 | -$4.74M | – | $11.45M | 10-K |
| 2020-12-31 | -$4.27M | – | $5.43M | 10-K |